Legal News

Samsung bioepis denies infringing blood treatment patent

Published on: 04 July 2024
Published by a Law360 reporter

Article summary

Law360, London: Samsung Bioepis has fought back against an application by Alexion to prevent it from selling a biosimilar version of a patented blood treatment drug by a rival, telling a court that this will not infringe the protections of an AstraZeneca subsidiary over the medicine.

Popular documents